US2005244436A1PendingUtilityA1

Combination Neisserial compositions

62
Assignee: CHIRON SRLPriority: May 19, 1999Filed: Nov 9, 2004Published: Nov 3, 2005
Est. expiryMay 19, 2019(expired)· nominal 20-yr term from priority
A61P 31/04A61P 37/04A61K 39/39C07K 14/22A61K 2039/55505A61K 2039/70A61K 2039/53A61K 39/095A61K 39/02A61K 38/164A61K 39/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N.meningitidis and N.gonorrhoeae.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a first isolated biological molecule from a  Neisseria  bacterium and a second isolated biological molecule from a  Neisseria  bacterium, wherein the first biological molecule is from ORF 287 and the second biological molecule is from ORF 961.  
     
     
         2 . The composition of  claim 1 , wherein said first biological molecule and said second biological molecule are from the same  Neisseria  species.  
     
     
         3 . The composition of  claim 1 , wherein said first biological molecule and said second biological molecule are from different  Neisseria  species.  
     
     
         4 . The composition of  claim 1 , wherein said first biological molecule and said second biological molecule are from  N.meningitidis  and/or  N.gonorrhoeae    
     
     
         5 . The composition of  claim 1 , wherein said first biological molecule and said second biological molecule are from  N.meningitidis.    
     
     
         6 . The composition of  claim 1 , wherein said first biological molecule comprises an amino acid sequence with at least 65% sequence identity to a contiguous sequence of amino acids selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and an immunogenic fragment comprising at least 10 contiguous amino acids of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4; and said second biological molecule comprises an amino acid sequence with at least 65% sequence identity to a contiguous sequence of amino acids selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, and an immunogenic fragment comprising at least 10 contiguous amino acids of SEQ ID NO:5 or SEQ ID NO:6:  
     
     
         7 . The composition of  claim 6 , wherein said first biological molecule is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.  
     
     
         8 . The composition of  claim 7 , wherein said first biological molecule is SEQ ID NO:1.  
     
     
         9 . The composition of  claim 6 , wherein said second biological molecule is selected from the group consisting of SEQ ID NO:5, and SEQ ID NO:6.  
     
     
         10 . The composition of  claim 9 , wherein said second biological molecule is SEQ ID NO:6.  
     
     
         11 . A composition comprising a first isolated biological molecule from a  Neisseria  bacterium and a second isolated biological molecule from a  Neisseria  bacterium, wherein 
 (a) said first biological molecule comprises an amino acid sequence with at least 65% identity to the contiguous sequence of amino acids of SEQ ID NO:1 or an immunogenic fragment comprising at least 10 contiguous amino acids of SEQ ID NO:1; and    (b) said second biological molecule comprises an amino acid sequence with at least 65% identity to the contiguous sequence of amino acids of SEQ ID NO:6 or an immunogenic fragment comprising at least 10 contiguous amino acids of SEQ ID NO:6.    
     
     
         12 . The composition of  claim 11 , wherein said first biological molecule comprises the amino acid sequence of SEQ ID NO:1, and said second biological molecule comprises the amino acid sequence of SEQ ID NO:6.  
     
     
         13 . The composition of  claim 1 , further comprising an adjuvant.  
     
     
         14 . The composition of  claim 12 , further comprising an adjuvant.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.